Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Å6 in asymptomatic CA125 progression of ovarian cancer
NCT00083928Phase 2Completed
- Sponsor
- Angstrom Pharmaceuticals
- Start
- May 2004
- Primary completion
- Feb 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of urokinase-derived peptide a6 in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC) (3 arms), sponsored by Angstrom Pharmaceuticals. Primary endpoints: Time to Clinical Progression and Safety and Adverse Events. Started May 2004; status: completed.
02
Drugs
urokinase-derived peptide a6
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00083928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083928.